Relmada Therapeutics, Inc. Common Stock RLMD
i
Market datapartial · fetched 2026-11-11T15:55:46.897Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:55:35.0325352Z
FundamentalsAlpha Vantage · unavailable
Relmada Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 8.55 | 354.6% | 99.4% | 2.93 | 274.4% | 38.0% |
| 25Δ | 7.90 | 369.9% | 86.3% | 3.11 | 258.9% | 34.8% |
| 30Δ | 7.36 | 374.5% | 76.1% | 3.29 | 243.5% | 31.6% |
| 35Δ | 7.00 | 361.8% | 70.4% | 3.48 | 228.0% | 28.5% |
| 40Δ | 6.64 | 349.1% | 64.8% | 3.66 | 212.5% | 25.3% |
| 45Δ | 6.28 | 336.5% | 59.2% | 3.84 | 197.1% | 22.1% |
| 50Δ | 5.92 | 323.8% | 53.6% | 4.02 | 181.6% | 18.9% |
| 55Δ | 5.55 | 311.1% | 47.9% | 4.20 | 166.2% | 15.8% |
| 60Δ | 5.19 | 298.4% | 42.3% | 4.38 | 150.7% | 12.6% |
| 65Δ | 4.83 | 285.7% | 36.7% | 4.57 | 135.3% | 9.4% |
| 70Δ | 4.47 | 273.1% | 31.1% | 4.75 | 119.8% | 6.2% |
| 75Δ | 4.11 | 260.4% | 25.4% | 4.93 | 104.3% | 3.0% |
| 80Δ | 3.75 | 247.7% | 19.8% | 5.70 | 139.9% | 1.8% |
20Δ
- Pseudo strike
- 8.55
- IV
- 354.6%
- B/E move
- 99.4%
- Pseudo strike
- 2.93
- IV
- 274.4%
- B/E move
- 38.0%
25Δ
- Pseudo strike
- 7.90
- IV
- 369.9%
- B/E move
- 86.3%
- Pseudo strike
- 3.11
- IV
- 258.9%
- B/E move
- 34.8%
30Δ
- Pseudo strike
- 7.36
- IV
- 374.5%
- B/E move
- 76.1%
- Pseudo strike
- 3.29
- IV
- 243.5%
- B/E move
- 31.6%
35Δ
- Pseudo strike
- 7.00
- IV
- 361.8%
- B/E move
- 70.4%
- Pseudo strike
- 3.48
- IV
- 228.0%
- B/E move
- 28.5%
40Δ
- Pseudo strike
- 6.64
- IV
- 349.1%
- B/E move
- 64.8%
- Pseudo strike
- 3.66
- IV
- 212.5%
- B/E move
- 25.3%
45Δ
- Pseudo strike
- 6.28
- IV
- 336.5%
- B/E move
- 59.2%
- Pseudo strike
- 3.84
- IV
- 197.1%
- B/E move
- 22.1%
50Δ
- Pseudo strike
- 5.92
- IV
- 323.8%
- B/E move
- 53.6%
- Pseudo strike
- 4.02
- IV
- 181.6%
- B/E move
- 18.9%
55Δ
- Pseudo strike
- 5.55
- IV
- 311.1%
- B/E move
- 47.9%
- Pseudo strike
- 4.20
- IV
- 166.2%
- B/E move
- 15.8%
60Δ
- Pseudo strike
- 5.19
- IV
- 298.4%
- B/E move
- 42.3%
- Pseudo strike
- 4.38
- IV
- 150.7%
- B/E move
- 12.6%
65Δ
- Pseudo strike
- 4.83
- IV
- 285.7%
- B/E move
- 36.7%
- Pseudo strike
- 4.57
- IV
- 135.3%
- B/E move
- 9.4%
70Δ
- Pseudo strike
- 4.47
- IV
- 273.1%
- B/E move
- 31.1%
- Pseudo strike
- 4.75
- IV
- 119.8%
- B/E move
- 6.2%
75Δ
- Pseudo strike
- 4.11
- IV
- 260.4%
- B/E move
- 25.4%
- Pseudo strike
- 4.93
- IV
- 104.3%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- 3.75
- IV
- 247.7%
- B/E move
- 19.8%
- Pseudo strike
- 5.70
- IV
- 139.9%
- B/E move
- 1.8%
Options history
No recorded observations
Biotechnology
RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…
More →ROIV
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that…
More →RPRX
Description unavailable
More →RVMD
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is…
More →RXRX
Description unavailable
More →RYTM
Description unavailable
More →